Español
Questions About Cancer? 1-800-4-CANCER
  • View entire document
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Adult Non-Hodgkin Lymphoma Treatment (PDQ®)

Changes to This Summary (12/04/2014)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Treatment Option Overview for Adult NHL

An editorial change was made to this section.

Treatment for Indolent, Noncontiguous Stage II/III/IV Adult NHL

An editorial change was made to this section.

Revised text to state that yttrium-90–labeled ibritumomab tiuxetan is available for previously untreated and relapsing patients with minimal or no marrow involvement with lymphoma (iodine-131–labeled tositumomab is no longer available because of commercial disengagement).

Treatment for Indolent, Recurrent Adult NHL

Revised text to state that durable responses to radiolabeled monoclonal antibodies, such as yttrium-90 ibritumomab (commercially available) and iodine-131 tositumomab (commercially unavailable), have also been reported before and after cytotoxic chemotherapy.

Treatment for Aggressive, Recurrent Adult NHL

Revised text to state that radiolabeled anti-CD20 monoclonal antibodies, such as iodine-131 tositumomab (no longer commercially available) and yttrium-90 ibritumomab, induce 60% to 80% response rates in patients with relapsed or refractory B-cell lymphoma.

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.

  • Updated: December 5, 2014